Anxiety and depression: Individual entities or two sides of the same coin?

International Journal of Psychiatry in Clinical Practice

Volumn 8, Issue SUPPL. 1, 2004, Pages 19-24

  Nutt, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anxiety disorders; Depression; PET scanning; SSRIs; Tryptophan depletion

Indexed keywords

5 HYDROXYTRYPTOPHAN; BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; DESIPRAMINE; FLUMAZENIL; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; TRYPTOPHAN HYDROXYLASE;

ANXIETY DISORDER; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; GENERALIZED ANXIETY DISORDER; HUMAN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RAPHE NUCLEUS; RELAPSE; SEROTONINERGIC NERVE CELL; SEROTONINERGIC TRANSMISSION; SOCIAL PHOBIA; STRESS;

EID: 6044226731     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500410005513     Document Type: Conference Paper

References (29)

1. Wittchen HU, Lecrubier Y, Besdo K, Nocon A (2003) Relationship among anxiety disorders. In: Nutt DJ, Ballenger JC (eds) Anxiety Disorders. London: Blackwells: 25-37.
2. Blier P, de Montigny C, Chaput Y (1988) Electrophysiological assessment of the effects of antidepressant treatments on the efficacy of 5-HT neurotransmission. Clin Neuropharmacol 11 (Suppl 2): S1-10.
3. Blier P, Pineyro G, el Mansari M et al (1998) Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann NY Acad Sci 861: 204-16.
4. Sargent PA, Kjaer KH, Bench CJ et al (2000) Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174-80.
5. Drevets WC, Frank E, Price JC (1999) PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46: 1375-87.
6. Nash JR, Sargent PA, Rabiner EA et al (2003) Altered 5-HT1a binding in panic disorder demonstrated by PET scanning. J Psychopharmacol 17 (Suppl 3): B23.
7. Neumeister A, Bain E, Nugent AC et al (2004) Reduced serotonin type IA receptor binding in panic disorder. J Neurosci 24: 589-91.
8. Lesch KP, Wiesmann M, Hoh A (1992) 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology (Berlin) 106: 111-7.
9. Marks I (1983) Are there anticompulsive or antiphobic drugs? Review of the evidence. Br J Psychiatry 143: 338-47.
10. Ballenger JC (2003) Selective serotonin reuptake inhibitors in the treatment of anxiety disorders. In: Nutt DJ, Ballenger JC (eds) Anxiety Disorders. London: Blackwells: 339-61.
11. Nutt DJ and Ballenger JC (eds) (2003) Anxiety Disorders. London: Blackwells.
12. Rosenberg R (2003) Treatment of anxiety disorders with tricyclic antidepressants. In: Nutt DJ, Ballenger JC (eds) Anxiety Disorders. London: Blackwells: 363-80.
13. The Clomipramine Collaborative Study Group (1991) Clomipramine in the treatment of obsessive compulsive disorder Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 48: 730-8.
14. Volavka J, Nezioglu F, Yaryura-Tobias JA (1985) Cloipramine and imipramine in obsessive compulsive disorders. Psychiatr Res 14: 85-93.
15. van Vliet IM, Westenberg HG, Den Boer JA (1993) MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berlin) 112: 483-9.
16. Den Boer JA, Van Vliet IM, Westenberg HG (1994) Recent advances in the psychopharmacology of social phobia. Prog Neuropsychopharmacol Biol Psychiatry 18: 625-45.
17. Braun P, Greenberg D, Dasberg H, Lerer B (1990) Core symptoms of PTSD unimproved by alprazolam treatment. J Clin Psychiatry 51: 236-8.
18. den Boer JA, Westenberg HG (1988) Effect of a serotonin and noradrenaline uptake blocker in panic disorder: a double blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharm 3: 59-4.
19. Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000) Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157: 493-505.
20. Malizia AL (2003) Brain imaging and anxiety disorders. In: Nutt DJ, Ballenger JC (eds) Anxiety Disorders. London: Blackwells: 201-28.
21. Nutt DJ (2001) Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 62 (Suppl 11): 22-7.
22. Nutt DJ, Bell CJ, Malizia AL (1998) Brain mechanisms of social anxiety disorder. J Clin Psychiatry 59 (Suppl 17): 4-11.
23. Delgado PL, Charney DS, Price LH (1990) Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47: 411-8.
24. Bell C, Abrams J, Nutt D (2001) Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178: 399-405.
25. Bell C, Forshall S, Adrover M et al (2002) Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 16: 5-14.
26. Barr LC, Goodman WK, McDougle CJ et al (1994) Tryptophan depletion in patients with obsessive compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 309-17.
27. Smeraldi E, Diaferia G, Erzegovesi S et al (1996) Tryptophan depletion in obsessive compulsive patients. Biol Psychiatry 40: 398-402.
28. Bell CJ, Nutt DJ (1998) Serotonin and panic. Br J Psychiatry 172: 465-71.
29. Argyropoulos S, Adrover M, Hoos SD et al (2002) Tryptophan depletion in treated social anxiety disorder: effects of autobiographical scripts and stressful speaking tasks. J Psychopharmacol 16 (Suppl): A51.